Fol. Biol. 2006, 52, 181-183
https://doi.org/10.14712/fb2006052060181
Simvastatin Could Prevent Increase of the Serum MMP-9/TIMP-1 Ratio in Acute Ischaemic Stroke
References
1. , C., Ruggieri, M., Giuliani, F., Liuzzi, G. M., Leante, R., Ricco, P., Livera, P., Trojano, M. (2003) Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J. Neuroimmunol. 136, 46-53.
<https://doi.org/10.1016/S0165-5728(03)00006-7>
2. , K., Dinakarpandian, D., Nagase, H., (2000) Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta 1477, 267-283.
<https://doi.org/10.1016/S0167-4838(99)00279-4>
3. , M., Leira, R., Serena, J., Pumar, J.M., Lizasoain, I., Castillo, J., Davalos, A. (2003) Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 34, 40-46.
<https://doi.org/10.1161/01.STR.0000046764.57344.31>
4. , J., Ro, I. (2004) Biochemical changes and inflammatory response as markers for brain ischaemia: molecular markers of diagnostic utility and prognosis in human clinical practice. Cerebrovasc. Dis. 17, suppl. 7-18.
<https://doi.org/10.1159/000074791>
5. , S., Coates, R., Gearing, A., Lury, J., Wells, G., Bone, E. (1995) Matrix metalloproteinases degrade myelin basic protein. Neurosci. Lett. 201, 223-226.
<https://doi.org/10.1016/0304-3940(95)12173-0>
6. , S., Miller, K. M., Clemens, J. M., Lury, J., Corkill, D., Anthony, D. C., Adams, S. E., Gearing, A. J. (1997) Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J. Neuroimmunol. 72, 155-161.
<https://doi.org/10.1016/S0165-5728(96)00179-8>
7. , H. P., Kieseier, B. C. (2000) The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J. Neuroimmunol. 107, 140-147.
<https://doi.org/10.1016/S0165-5728(00)00225-3>
8. , J., Szczepańska-Szerej, A., Wojczal, J., Bielewicz, J., Stryjecka-Zimmer, M., Stelmasiak, Z. (2006) Influence of HMG-CoA reductase inhibitor (simvastatin) on serum matrix metalloproteinase-2 and -9 activity in acute ischemic stroke. Polish J. Environ. Stud. 15, 80-83.
9. , J. (2005) Treatment with statins in the acute phase of ischemic stroke. Exp. Rev. Neurother. 5, 211-221.
<https://doi.org/10.1586/14737175.5.2.211>
10. , J., Chacon, P., Krupinski, J., Millan, M., Hereu, P., Molina, C., Quintana, M., Alvarez-Sabin, J. (2004) Safety and efficacy of statins in the acute phase of ischemic stroke: the MISTICS trial. Stroke 34, 293.
11. , G., Van den Steen, P. E., Van Damme, J. (2001) Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol. 22, 571-579.
<https://doi.org/10.1016/S1471-4906(01)02023-3>
12. , M. A., Wettstein, J. G. (2001) Elements of cerebral mocrovascular ischaemia. Brain Res. Rev. 36, 23-34.
<https://doi.org/10.1016/S0165-0173(01)00062-5>
13. , A. M., Sole, S., Justica, C. (2001) Expression and activation of matrix metalloproteinase-2 and -9 in rat brain after transient focal cerebral ischaemia. Neurobiol. Dis. 8, 834-846.
<https://doi.org/10.1006/nbdi.2001.0435>
14. , P. E., Spark, J. I., Cowled, P. A., Fitridge, R. A. (2004) The role of statins in vascular disease. Eur. J. Vasc. Endovasc. Surg. 27, 6-16.
<https://doi.org/10.1016/j.ejvs.2003.09.014>
